

**ASX Announcement | 1 July 2019
Vioneering Technologies (ASX:VTI)**

Extension of voting period for special meeting of stockholders

Atlanta, Georgia, USA 1 July 2019: US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Vioneering Technologies, Inc (ASX: VTI), (Vioneering or Company)**, announces an extension to the voting period in respect of the Company's special meeting of stockholders to be held at Johnson Winter & Slattery's Sydney office, Level 25, 20 Bond Street, Sydney NSW Australia on Tuesday, 2 July 2019 at 10.00 a.m. Australian Eastern Standard Time (on Monday, 1 July 2019 at 8.00 p.m. US Eastern Daylight Time) (**Meeting**).

The Company will accept voting instructions from CDI holders until 5.00 p.m. today, Monday, 1 July 2019 Australian Eastern Standard Time (3.00 a.m. Monday, 1 July 2019 US Eastern Daylight Time), and encourages CDI holders who have not provided voting instructions to do so during the extended voting period.

The Company confirms that the record date in respect of the entitlement to vote at the Meeting has not changed from 7.00 p.m. Australian Eastern Standard Time on Friday, 14 June 2019 (i.e. 5.00 a.m. US Eastern Daylight Time on Friday, 14 June 2019).

For all enquiries call:
(within Australia) 1300 850 505
(outside Australia) +61 3 9415 4000

For more information, please contact:

Vioneering Technologies

Stephen Snowdy
CEO
E: ssnowdy@vtivision.com

Investor & Media Relations

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

About Vioneering Technologies

Vioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Vioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Vioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

Foreign Ownership Restrictions

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.